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ate, positive reinforcement with a maintenance inhaler has the
potential for increasing satisfaction and persistence with treat-
ment and improving health status. METHODS: Two qualitative
studies using structured interviews were conducted to under-
stand patient perceptions associated with feeling an asthma 
medication working right away and develop a method for 
quantifying this perception in clinical trials. RESULTS: Study I:
56 asthma patients (44 yrs, SD = 18) were asked about the
concept of feeling their medication working right away and
whether it was important. Respondents described the perception
as breathing easier and deeper and felt this would be meaning-
ful and reassuring. Five items, labeled the “Onset of Effect Ques-
tionnaire” (OEQ), were developed for use as a weekly diary.
Items to identify patients who perceived their medication
working right away and those satisﬁed with the perception were
of particular interest. Items were pre-tested via telephone inter-
view (n = 11) and found to be clear, comprehensive, and easy to
complete. Patients understood the concept and the concise,
weekly diary approach. Study II: 39 asthma patients (37 years,
SD = 15) participated in cognitive debrieﬁng interviews to test
item interpretation and gather additional data on perception and
its value. Respondents characterized the items as clear, inter-
preted “right away” as immediately to <15 minutes after inhala-
tion, and had no difﬁculty interpreting the 1-week recall.
CONCLUSION: Patients understand and value the concept of
perceiving a maintenance therapy working right away. A concise,
weekly recall diary approach can be used to quantify this
attribute in clinical trials.
ALLERGY/ASTHMA—Patient-Reported Outcomes
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OBJECTIVES: To determine the relationship between Health-
Related Quality of Life (HRQL) and asthma control in children
as deﬁned by the Canadian Pediatric Asthma Consensus Guide-
lines (CPACG). METHODS: Cross-sectional data on 879 chil-
dren aged 1 to 18 from a completed study of children with a
diagnosis of asthma were analyzed. The Pediatric Asthma
Quality of Life Questionnaire (PAQLQ) was administered by
interview and information regarding the following asthma
control parameters was collected: daytime symptoms, night-time
symptoms, beta2-agonist use, physical activity level, exacerba-
tions, and school absences. The Pearson correlation was calcu-
lated between the asthma control parameters satisﬁed and the
PAQLQ domain scores. The level of agreement between the top
quintile of each PAQLQ domain (≥80th percentile) and accept-
able asthma control (all six parameters satisﬁed) was evaluated
using the kappa statistic to measure agreement beyond chance.
This was also done for unacceptable control (four or fewer out
of six parameters satisﬁed) and the bottom quintile PAQLQ
scores. RESULTS: The correlations between the number of
asthma control parameters and the PAQLQ domains were 0.507,
0.467, and 0.474, (p < 0.0001) for the symptoms, activity limi-
tations, and emotional function domains respectively. The kappa
for the top quintile of each PAQLQ domain and acceptable
control was 0.206 for symptoms, 0.117 for activity limitations,
and 0.184 for emotional function. The level of agreement
between unacceptable control for the lowest quintiles domains
was 0.128, 0.114, and 0.133 for symptoms, activity, and emo-
tional function, respectively. CONCLUSION: The strong rela-
tionship between asthma control and HRQL supports a shared
focus on control and quality of life in the CPACG. The low level
of agreement between the control levels and the PAQLQ quin-
tiles suggests further study is needed to determine optimal cut-
offs for control levels and the marginal beneﬁts from quality of
life measures.
PAA25
IMPACT OF ALLERGIC RHINITIS ON WORK PRODUCTIVITY
Beyer A1, Szeinbach SL1, Seoane-Vazquez E1,Williams PB2
1Ohio State University, Columbus, OH, USA, 2Univerity of Missouri,
Kansas City, MO, USA
OBJECTIVES: Patients with allergic rhinitis (AR) experience a
multitude of symptoms that usually compromise some aspect of
lifestyle and work productivity. METHODS: A questionnaire
was developed and mailed to 2065 patients enrolled in a 500,000
member managed care organization. Patients were identiﬁed by
diagnostic codes for AR as determined from a retro-examination
of medical and prescription claims records from January 1, 2000
to December 31, 2000. A ten-point scale was used to assess the
impact of allergy symptoms on work productivity adapted from
the Allergy-Speciﬁc Work Productivity and Activity Impairment
questionnaire. RESULTS: On average respondents (n = 577)
reported one hour of work missed per week because of allergy
symptoms (range = 0–32 hours). For patients seeing family physi-
cians, 66 (55.0%) reported that either a blood or skin test was
valuable during the process of allergy diagnosis, 82 (73.9%) for
allergists, and 56 (65.1%) for self-managed patients who were
previously tested. Chi-square and analysis of variance tests also
revealed signiﬁcant differences among three care groups (p <
0.05) for years with allergies, symptoms, family history, testing,
immunotherapy, test value, and prescribed antihistamine use.
Multiple linear regression analysis revealed that sleep, health-
related quality of life (HRQoL), certain allergy symptoms and
prescribed antihistamines were signiﬁcantly related to work pro-
ductivity. CONCLUSION: The ability of individuals with AR to
engage in productive work is inﬂuenced by sleep, HRQoL, spe-
ciﬁc symptoms, and prescribed antihistamine use. Appropriate
clinical evaluation and an accurate diagnosis using either or both
speciﬁc IgE testing or skin testing is needed to develop a holistic
approach for treatment.
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OBJECTIVES: To determine the socioeconomic predictors of
asthma control in children, as deﬁned by the Canadian Pediatric
Asthma Consensus Guidelines (CPACG). METHODS: A cross-
sectional design was used to analyze data from a completed
CIHR-funded study based on 879 children from seven sites in
the Greater Toronto Area between 2000–2003. Children were
aged 1 to 18 years with a documented diagnosis of asthma and
a prescription for an asthma medication in the previous year.
Multiple linear regressions were used to analyze asthma control
based on six equally weighted control parameters (daytime
symptoms, night-time symptoms, need for beta2-agonists, phys-
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ical activity level, exacerbations, and school absences). The
impact of the following factors was investigated: family income
adequacy, parent education, parent employment, ethnicity,
parent immigration, language, parent marital status, and physi-
cal environment characteristics. The CPACG and Global Initia-
tive for Asthma (GINA) guideline deﬁnitions of asthma control
were compared. RESULTS: Only 11% of patients met the
requirements for acceptable control by satisfying all six para-
meters, while 20% satisﬁed ﬁve parameters, and 69% satisﬁed
four or fewer parameters. The multiple regressions indicated that
income adequacy had an impact on asthma control. Children
from families in the middle income adequacy quintile tended 
to have worse control. Higher numbers of asthma triggers,
increased physician or specialist visits, and daily use of anti-
inﬂammatories, were associated with lower levels of control. The
CPACG and GINA guidelines had a high level of agreement
(Weighted kappa = 0.74, p < 0.0001), although it was more dif-
ﬁcult to achieve acceptable asthma control in the CPACG guide-
lines. CONCLUSION: Despite the established effectiveness of
inhaled corticosteroids in the prevention of asthma exacerba-
tions, poor control remains a problem which was affected by
family income adequacy.
ARTHRITIS—Clinical Outcomes Studies
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OBJECTIVES: Rheumatoid arthritis (RA), psoriasis (PS),
Crohn’s disease (CD) and ulcerative colitis (UC) are autoimmune
related diseases. The purpose of this study was to estimate the
mortality rate of patients for each of these four conditions, rel-
ative to the overall population, adjusting for age and sex differ-
ences of the each patient group. METHODS: The analysis was
based on the THIN database for 2004. This data source is based
on the registration in GP-practices for a 4% representative
sample of the overall UK population. From the overall-popula-
tion sample (n = 2.278.100), patients were identiﬁed based on
the READ codes for each of these conditions in the previous 4
years. A subgroup of severe cases was identiﬁed, based on pre-
vious drug treatment. The standardised mortality ratio (SMR),
deﬁned as the proportion of the observed number of deaths and
the expected number, based on the age and gender speciﬁc 
mortality rates for the overall population, was calculated for
each patient group. 95% conﬁdence intervals were calculated.
RESULTS: 2% of the studied population suffers from one or
more of the four diseases: RA (0.44%), PS (1.3%), CD (0.14%)
or UC (0.16%). The SMR for all four disease conditions com-
bined was signiﬁcantly higher (132 [122,143]) compared to the
global UK population. Within the four groups, RA (158
[139,179]), CD (165 [108,241]) and PS (116 [103,130]) all
showed statistically increased mortality. The SMR was (ns)
higher for UC (122, [89,163]). Within each of these disease
groups, mortality was higher for severe patients, but did not
reach statistical signiﬁcance, possibly due to the relatively small
sample size of these subgroups. CONCLUSION: Patients suf-
fering from Crohn’s disease and rheumatoid arthritis have a 60%
increased mortality compared to the overall UK population.
Mortality is about 20% higher for patients with psoriasis and
ulcerative colitis.
ARTHRITIS—Cost Studies
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OBJECTIVES: To assess the health care utilization and associ-
ated costs for osteoarthritis (OA) patients, depending on the
primary drug prescribed for pain management. METHODS: A
claims database of privately insured patients (covering 31
employers, 1999–2004) was used to identify OA patients (ICD-
9-CM 715.XX) OA patients were categorized by primary pain
drug treatment—deﬁned as greatest days supply, 2003–2004—
for pain management (tramadol, acetaminophen w/codeine,
Cox-IIs, NSAIDS, short-acting opioids). A tramadol monother-
apy cohort was also constructed in which patients were pre-
scribed only tramadol for their pain (i.e., these patients did not
receive any of the other primary pain drugs listed above.) Mean
annual per patient health care costs were calculated for each drug
treatment cohort from a private payer’s perspective. RESULTS:
OA patients (n = 32,043) were often prescribed multiple drugs
simultaneously and/or sequentially to manage pain. Average
annual direct medical costs for OA patients were $8602 (ranging
from $6011 to $13,964 depending on the drug treatment
cohort). Average annual drug costs for OA patients were $2941
(ranging from $2108 to $8498 depending on the drug treatment
cohort). The tramadol monotherapy cohort had lower costs than
other cohorts. Cohort cost differences reﬂect, in part, more
severe comorbidity proﬁle and complex temporal treatment pat-
terns. CONCLUSION: Average annual direct costs of OA
patients were $11,543, which varies by drug treatment cohort.
OA patients use multiple simultaneously and/or sequentially to
treat their pain. Prescribing tramadol earlier to treat OA may
reduce therapy switching and associated costs and a once-a-day
version of tramadol may offer additional convenience, tolerabil-
ity and sleep improvement beneﬁts for OA patients. Future
research is needed to identify the temporal patterns of tramadol
use and associated outcomes.
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OBJECTIVES: To estimate incremental cost-utility ratios for
lumiracoxib relative to celecoxib for treating osteoarthritis (OA)
in Canada. Secondary comparators including six common treat-
ment algorithms (non-steroidal anti-inﬂammatory drugs with
and without proton pump inhibitors) were also evaluated.
METHODS: An existing Markov model with 3 month cycle
lengths and 5 year time horizon was adapted for Canada. Analy-
ses were performed from the third-party perspective of the
Ontario Ministry of Health. Treatments were assumed to be
equally efﬁcacious in treating symptoms of OA. Data on differ-
ences in rates of gastrointestinal (GI) and other (renal, skin,
hepatic) adverse events were obtained from published random-
ized trials. Quality-adjusted life years (QALYs) were calculated
separately for subgroups deﬁned a priori for age, sex, aspirin use,
and history of GI bleed. Common treatment pathways were
elicited from clinical experts. Costs of hospitalizations, labora-
tory tests, professional fees, and medications were obtained from
